TIDMABC

ABCAM PLC

05 November 2021

ABCAM PLC

Vesting of 'AbShare', Abcam's All Employee Share Scheme

5 November 2021, Cambridge, UK - Abcam plc ("Abcam" or "the Company") (AIM LSE: ABC; Nasdaq: ABCM), is delighted to announce that the performance conditions have been met for AbShare, the Group's all employee share scheme launched in 2018, and all awards will vest in full on Monday 8 November.

The scheme will see approximately 1.8 million shares awarded to over 1,350 employees (excluding the Executive Directors) who elected to participate in the plan, which has won multiple awards, including being voted the most innovative and creative share plan by the Global Equity Awards in 2019.

Shares under the AbShare plan were awarded at GBP12.19 a share, the prevailing price in November 2018. This compares with the closing price as of 4 November 2021 of GBP16.91.

Commenting on the news, Nick Skinner, SVP of HR, said:

"AbShare was launched in 2018 with the goal of fostering greater employee ownership across our entire global worksforce. I am delighted that as that programme vests, approximately 90% of our global team are now shareholders in the Company."

--- Ends ---

Abcam plc

+44 (0) 1223 696 000

James Staveley, VP Investor Relations

Marc Perkins, Company Secretary

Numis - Nominated Advisor & Joint Corporate Broker

+ 44 (0) 20 7260 1000

Garry Levin / Freddie Barnfield / Duncan Monteith

About Abcam plc

As an innovator in reagents and tools, Abcam's purpose is to serve life science researchers globally to achieve their mission, faster. Providing the research and clinical communities with tools and scientific support, the Company offers highly validated antibodies, assays and other research tools to address important targets in critical biological pathways.

Already a pioneer in data sharing and ecommerce in the life sciences, Abcam's ambition is to be the most influential company in life sciences by helping advance global understanding of biology and causes of disease, which, in turn, will drive new treatments and improved health.

Abcam's worldwide customer base of approximately 750,000 life science researchers uses Abcam's antibodies, reagents, biomarkers and assays. By actively listening to and collaborating with these researchers, the Company continuously advances its portfolio to address their needs. A transparent programme of customer reviews and datasheets, combined with an industry-leading validation initiative, gives researchers increased confidence in their results.

Founded in 1998 and headquartered in Cambridge, UK, the Company has served customers in more than 130 countries. Abcam's ordinary shares are listed on the London Stock Exchange (AIM: ABC) and its American Depositary Shares (ADSs) trade on the Nasdaq Global Market (Nasdaq: ABCM).

For more information, please visit corporate.abcam.com .

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRAEELFBFFLFFBQ

(END) Dow Jones Newswires

November 05, 2021 11:19 ET (15:19 GMT)

Abcam (NASDAQ:ABCM)
Historical Stock Chart
From Apr 2022 to May 2022 Click Here for more Abcam Charts.
Abcam (NASDAQ:ABCM)
Historical Stock Chart
From May 2021 to May 2022 Click Here for more Abcam Charts.